Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia
- 18 February 2010
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 115 (7), 1394-1405
- https://doi.org/10.1182/blood-2009-05-218560
Abstract
To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic leukemia (ALL) at high risk for relapse, we profiled pretreatment leukemic cells in 207 uniformly treated children with high-risk B-precursor ALL. A 38-gene expression classifier predictive of relapse-free survival (RFS) could distinguish 2 groups with differing relapse risks: low (4-year RFS, 81%, n = 109) versus high (4-year RFS, 50%, n = 98; P < .001). In multivariate analysis, the gene expression classifier (P = .001) and flow cytometric measures of minimal residual disease (MRD; P = .001) each provided independent prognostic information. Together, they could be used to classify children with high-risk ALL into low- (87% RFS), intermediate- (62% RFS), or high- (29% RFS) risk groups (P < .001). A 21-gene expression classifier predictive of end-induction MRD effectively substituted for flow MRD, yielding a combined classifier that could distinguish these 3 risk groups at diagnosis (P < .001). These classifiers were further validated on an independent high-risk ALL cohort (P = .006) and retainedindependent prognostic significance (P < .001) in the presence of other recently described poor prognostic factors (IKAROS/IKZF1 deletions, JAK mutations, and kinase expression signatures). Thus, gene expression classifiers improve ALL risk classification and allow prospective identification of children who respond or fail current treatment regimens. These trials were registered at http://clinicaltrials.gov under NCT00005603.This publication has 46 references indexed in Scilit:
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- Acute lymphoblastic leukaemiaThe Lancet, 2008
- New therapeutic strategies for the treatment of acute lymphoblastic leukaemiaNature Reviews Drug Discovery, 2007
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Blood, 2006
- Treatment of Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2006
- Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2005
- Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to TreatmentThe New England Journal of Medicine, 2004
- Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cellsNature Genetics, 2003
- Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profilingCancer Cell, 2002
- Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.Journal of Clinical Oncology, 1996